Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey L Uy

Showing results (1-10 of 145) with videos related to

Pageof 15
Sort By:
Blood|December 23, 2021
Turning AML targets inside outGeoffrey L Uy
JCO Oncology Practice|May 13, 2020
All I Really Need to Know I Learned From Pediatric OncologistsGeoffrey L Uy
Current Hematologic Malignancy Reports|April 30, 2015
Targeting the microenvironment in acute myeloid leukemiaArmin Rashidi, Geoffrey L Uy
Current Hematologic Malignancy Reports|October 4, 2018
Bispecific Antibodies for the Treatment of Acute Myeloid LeukemiaDaniel G Guy, Geoffrey L Uy
Best Practice & Research. Clinical Haematology|April 1, 2019
Choosing induction chemotherapy in therapy-related acute myeloid leukemiaLauren K Shea, Geoffrey L Uy
Best Practice & Research. Clinical Haematology|December 6, 2020
CD123 bi-specific antibodies in development in AML: What do we know so far?Michael J Slade, Geoffrey L Uy
Blood|January 24, 2025
The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatmentSameem Abedin, Geoffrey L Uy, Laura C Michaelis
Leukemia & Lymphoma|January 2, 2009
Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitorsMike G Martin, John F Dipersio, Geoffrey L Uy
Expert Opinion on Biological Therapy|October 14, 2008
Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cellsGeoffrey L Uy, Michael P Rettig, Amanda F Cashen
Blood|December 4, 2023
Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to actionVijaya Raj Bhatt, Geoffrey L Uy, Heidi D Klepin
Pageof 15

Showing results (1-10 of 145) with videos related to

Sort By:
Pageof 15
Blood|December 23, 2021
Turning AML targets inside outGeoffrey L Uy
JCO Oncology Practice|May 13, 2020
All I Really Need to Know I Learned From Pediatric OncologistsGeoffrey L Uy
Current Hematologic Malignancy Reports|April 30, 2015
Targeting the microenvironment in acute myeloid leukemiaArmin Rashidi, Geoffrey L Uy
Current Hematologic Malignancy Reports|October 4, 2018
Bispecific Antibodies for the Treatment of Acute Myeloid LeukemiaDaniel G Guy, Geoffrey L Uy
Best Practice & Research. Clinical Haematology|April 1, 2019
Choosing induction chemotherapy in therapy-related acute myeloid leukemiaLauren K Shea, Geoffrey L Uy
Best Practice & Research. Clinical Haematology|December 6, 2020
CD123 bi-specific antibodies in development in AML: What do we know so far?Michael J Slade, Geoffrey L Uy
Blood|January 24, 2025
The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatmentSameem Abedin, Geoffrey L Uy, Laura C Michaelis
Leukemia & Lymphoma|January 2, 2009
Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitorsMike G Martin, John F Dipersio, Geoffrey L Uy
Expert Opinion on Biological Therapy|October 14, 2008
Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cellsGeoffrey L Uy, Michael P Rettig, Amanda F Cashen
Blood|December 4, 2023
Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to actionVijaya Raj Bhatt, Geoffrey L Uy, Heidi D Klepin
Pageof 15